Literature DB >> 29174966

Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis.

Yee Ting Lee1, Mengqi Gong2, Alex Chau3, Wing Tak Wong4, George Bazoukis5, Sunny Hei Wong6, Konstantinos Lampropoulos5, Yunlong Xia7, Guangping Li2, Martin C S Wong8, Tong Liu2, William K K Wu9, Gary Tse10.   

Abstract

OBJECTIVES: Pentraxin-3 (PTX-3) is a multi-functional pattern recognition molecule produced by various cell types of peripheral tissues in different infections. It is raised in sepsis, but its values in predicting disease severity or mortality outcomes have been controversial. Therefore, we conducted a systematic review and meta-analysis of these associations.
METHODS: PubMed and Embase were searched until July 18, 2017 for studies that evaluated the relationship between PTX-3 levels and disease severity or mortality in sepsis.
RESULTS: A total of 23 and 10 entries were retrieved from both databases, respectively, of which 16 studies were included in the final meta-analysis. A total of 3001 patients (56% male, mean age 63 ± 15 years; mean follow-up duration of 207 days) were analysed. PTX-3 was significantly higher in patients with more severe sepsis compared to those with less severe sepsis (standard mean difference = 18.5 ng/mL, standard error: 4.5 ng/mL, P < 0.0001) and higher in non-survivors compared to survivors (standard mean difference = 40.3 ng/mL, standard error: 6.8 ng/mL, P < 0.0001). Elevated PTX-3 levels significantly increased the risk of all-cause mortality (hazard ratio: 1.91, 95% CI: 1.53 to 2.46, P < 0.0001).
CONCLUSIONS: PTX-3 significantly predicts disease severity and mortality in sepsis.
Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mortality; Pentraxin-3; Sepsis; Septic shock; Severity

Mesh:

Substances:

Year:  2017        PMID: 29174966     DOI: 10.1016/j.jinf.2017.10.016

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  19 in total

1.  Response to Letter to the Editor: Deep waters of science.

Authors:  Gary Tse; Adrian Baranchuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-06-01       Impact factor: 1.468

2.  Impact of epidural analgesia on the systemic biomarker response after hepatic resection.

Authors:  Diego Vicente; Miguel Patino; Rebecca Marcus; Heather Lillmoe; Preparim Limani; Timothy Newhook; Andy Lee; Ching-Wei Tzeng; Yun Segraves-Chun; David Tweardy; Vijaya Gottumukkala; Jean-Nicolas Vauthey; Thomas Aloia; Juan P Cata
Journal:  Oncotarget       Date:  2019-01-15

3.  Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies.

Authors:  Eszter Trojnar; Mihály Józsi; Zsóka Szabó; Marienn Réti; Péter Farkas; Kata Kelen; George S Reusz; Attila J Szabó; Nóra Garam; Bálint Mikes; György Sinkovits; Blanka Mező; Dorottya Csuka; Zoltán Prohászka
Journal:  Front Immunol       Date:  2019-02-25       Impact factor: 7.561

Review 4.  The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis.

Authors:  Rémi Porte; Sadaf Davoudian; Fatemeh Asgari; Raffaella Parente; Alberto Mantovani; Cecilia Garlanda; Barbara Bottazzi
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

5.  Galectin-3 and risk of atrial fibrillation: A systematic review and meta-analysis.

Authors:  Mengqi Gong; Angel Cheung; Qun-Shan Wang; Guangping Li; Christos A Goudis; George Bazoukis; Gregory Y H Lip; Adrian Baranchuk; Panagiotis Korantzopoulos; Konstantinos P Letsas; Gary Tse; Tong Liu
Journal:  J Clin Lab Anal       Date:  2020-01-09       Impact factor: 2.352

6.  A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.

Authors:  Carlo Contini; Carla Enrica Gallenga; Giampiero Neri; Martina Maritati; Pio Conti
Journal:  Med Hypotheses       Date:  2020-05-24       Impact factor: 1.538

7.  Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19.

Authors:  Enrico Brunetta; Marco Folci; Barbara Bottazzi; Maria De Santis; Giuseppe Gritti; Alessandro Protti; Sarah N Mapelli; Stefanos Bonovas; Daniele Piovani; Roberto Leone; Ilaria My; Veronica Zanon; Gianmarco Spata; Monica Bacci; Domenico Supino; Silvia Carnevale; Marina Sironi; Sadaf Davoudian; Clelia Peano; Francesco Landi; Fabiano Di Marco; Federico Raimondi; Andrea Gianatti; Claudio Angelini; Alessandro Rambaldi; Cecilia Garlanda; Michele Ciccarelli; Maurizio Cecconi; Alberto Mantovani
Journal:  Nat Immunol       Date:  2020-11-18       Impact factor: 25.606

8.  A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension.

Authors:  King Sum Luk; Christina Ip; Meng-Qi Gong; Sunny Hei Wong; William Kk Wu; Mei Dong; Guang-Ping Li; Ka Pang Chan; Yi-Mei Du; Tong Liu; Martin Cs Wong; David Shu Cheong Hui; Gary Tse
Journal:  J Geriatr Cardiol       Date:  2017-12       Impact factor: 3.327

9.  Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis.

Authors:  Timothy L Tipoe; William K K Wu; Lilianna Chung; Mengqi Gong; Mei Dong; Tong Liu; Leonardo Roever; Jeffery Ho; Martin C S Wong; Matthew T V Chan; Gary Tse; Justin C Y Wu; Sunny H Wong
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

10.  Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions.

Authors:  Juhyun Song; Dae Won Park; Sungwoo Moon; Han-Jin Cho; Jong Hak Park; Hyeri Seok; Won Seok Choi
Journal:  BMC Infect Dis       Date:  2019-11-12       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.